TransMedics Q4 revenue $81.2M (+159% YoY); guides FY2024 $360-370M

TransMedics Group, Inc.

2023-FY EPS reported -$0.77 revenue$241,623,000

Q4 2023 revenue $81.2M (+159% YoY); net income $4.0M ($0.12 EPS) vs loss of $6.7M in Q4 2022.
Full-year 2023 revenue $241.6M (+159% YoY); net loss narrowed to $25.0M from $36.2M.
Gross margin declined to 59% (Q4) and 64% (FY) from 66% and 70% respectively.
Cash position $394.8M as of Dec 31, 2023.
FY2024 revenue guidance $360-370M, representing 49%-53% growth over 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported the year ended December 31, 2023 results: revenue $241.6 million, net income $(25.0) million.

Period: the year ended December 31, 2023
Revenue: $241.6 million
Net income: $(25.0) million
Result: reported results

Exact text from the filing

December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022 ▪ Generated net income of $4.0 million or $0.12 per share in the fourth quarter of 2023 “2023 was a

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported full-year 2024 results: revenue $360 million to $370 million. Guidance initiated.

Period: full-year 2024
Revenue: $360 million to $370 million
Guidance: initiated
Result: guidance update

Exact text from the filing

TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company’s prior year revenue.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TransMedics Group, Inc. reported the quarter ended December 31, 2023 results: revenue $81.2 million, net income $4.0 million, EPS $0.12 per share.

Period: the quarter ended December 31, 2023
Revenue: $81.2 million
Net income: $4.0 million
EPS: $0.12 per share
Result: reported results

Exact text from the filing

patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the

View on SEC.gov

1052 earnings releases filed in the last 30 days. Browse all earnings releases →

TransMedics Group, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-020175

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.